I’m a postdoctoral researcher in the Engreitz lab at Stanford University, Department of Genetics. My research bridges basic and translational science, leveraging cutting-edge molecular technologies to unravel the genetic and molecular mechanisms underlying complex human diseases. With over a decade of experience in molecular and cellular biology, my work has been published in top-tier journals such as Nature, Nature Cancer, Nature Chemical Biology, and Circulation.
In my current postdoctoral work, I focus on deciphering how cis-regulatory elements, such as enhancers, govern gene expression and how genetic variations influence these regulatory processes. I apply single-cell multi-omics techniques, including RNA-seq and ATAC-seq, alongside computational modeling, to create comprehensive genome-wide maps of enhancer-gene interactions across diverse cell types, states, and dynamic cellular trajectories using induced pluripotent stem cells (iPSCs) as a model system. I use these maps to predict the functions of candidate disease variants and perform high-throughput CRISPR perturbation screens to dissect the roles of variants, regulatory elements, and genes.
During my doctoral research at Albert Einstein College of Medicine, I investigated the molecular mechanisms behind cardiomyopathies induced by cancer treatment. Through a combination of biochemical, cellular, and in vivo mouse model approaches, I identified inhibition of the mitochondrial cell death protein BAX as a promising therapeutic strategy to safeguard the heart from the harmful effects of chemotherapy. This pioneering work culminated in the development of a first-in-class small molecule inhibitor targeting BAX, a protein once deemed ''undruggable.''
I aim to apply advanced technologies to address complex biological questions and drive therapeutic innovation. Let’s connect to explore opportunities for collaboration and scientific advancement!
The Impact of Genomic Variation on Function (IGVF) Consortium
Nature | 2024
Gasdermin D permeabilization of mitochondrial inner and outer membranes accelerates and enhances pyroptosis
Immunity | 2023
Genetic determinants of the interventricular septum are linked to ventricular septal defects and hypertrophic cardiomyopathy
Oligogenic Architecture of Rare Noncoding Variants Distinguishes 4 Congenital Heart Disease Phenotypes
Computational estimates of annular diameter reveal genetic determinants of mitral valve function and disease
JCI insight | 2022
A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy
Nature cancer | 2020
ATG16L1 autophagy pathway regulates BAX protein levels and programmed cell death
Fundamental mechanisms of regulated cell death and implications for heart disease
Physiological reviews | 2019
Small-molecule allosteric inhibitors of BAX
Nature chemical biology | 2019
A mouse model for the most common form of heart failure
Nature | 2019
SNAP23 regulates BAX-dependent adipocyte programmed cell death independently of canonical macroautophagy
An Akt3 splice variant lacking the serine 472 phosphorylation site promotes apoptosis and suppresses mammary tumorigenesis
Cancer research | 2018
Grounding cardio-oncology in basic and clinical science
Circulation | 2017
Death receptor signaling in the heart: cell survival, apoptosis, and necroptosis
Circulation | 2017
Troponin release following brief myocardial ischemia: apoptosis versus necrosis
Genetic determinants of interventricular septal anatomy and the risk of ventricular septal defects and hypertrophic cardiomyopathy
medRxiv | 2021
Direct Small Molecule BAX Inhibition as a Novel Therapeutic Strategy to Protect the Heart Against Cancer Therapies (PhD Thesis)
Yeshiva University | 2018
Small molecule BAX inhibitors and uses thereof
US Patent | 2024
Grants awarded to better understand the No. 1 birth defect
American Heart Association Newsroom | Feb 2023
8 research projects totaling $900K funded to focus on congenital heart defects
American Heart Association Newsroom | Feb 2021
DULGUUN Amgalan, Ph.D. at Broad Institute of MIT and Harvard - On Leading Genetic Heart Disease Research
Hobby Alumni, by Nomko Baatar | Apr 2020
Experimental Drug May Prevent Chemotherapy Drug from Damaging the Heart
Albert Einstein College of Medicine | Jan 2020